Interleukin 17A inhibitor secukinumab in the treatment of patients with psoriatic arthritis

Cover Page

Cite item

Full Text

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory joint disease associated with psoriasis and characterized by various presentation, course, and response to treatment. A better understanding of the pathogenesis has led to the development of targeted therapeutic agents and innovative treatment strategies for PsA. The article is dedicated to a drug targeting interleukin-17A. Secukinumab is a fully human monoclonal antibody that selectively targets interleukin (IL) 17A, a pro-inflammatory cytokine involved in the pathogenesis of PsA. Secukinumab is the first antibody against IL 17 approved in many countries for PsA treatment in adult patients. In the Phase III FUTURE trial, secukinumab 150 and 300 mg subcutaneously showed high efficacy on disease activity in patients previously treated with non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and / or tumor necrosis factor (TNF) inhibitors and maintaining the effect for a long time of treatment (more than 5 years). In addition, in studies FUTURE 1 and 5 secukinumab suppressed structural joint damage and was associated with consistently low rates of radiological progression after 1–3 years of treatment. Treatment with secukinumab improved physical function and quality of life and was generally well tolerated in both short and long term. Secukinumab is effective in all key PsA domains and therefore represents a treatment option that may be an alternative to TNF inhibitors and other DMARDs in adult patients with PsA.

About the authors

N. A. Shostak

Department of Faculty Therapy named after Academician A. I. Nesterov, Pirogov Russian National Research Medical University, Ministry of Health of Russia

ORCID iD: 0000-0003-4669-1006

1 Ostrovityanova St., Moscow 117997

Russian Federation

D. Yu. Andriyashkina

Department of Faculty Therapy named after Academician A. I. Nesterov, Pirogov Russian National Research Medical University, Ministry of Health of Russia

Author for correspondence.
Email: andryashkina.darya@yandex.ru
ORCID iD: 0000-0001-8266-6022

Daria Yurievna Andriyashkina 

1 Ostrovityanova St., Moscow 117997

Russian Federation

A. S. Dvornikov

Department of Dermatovenerology named after Academician Yu. K. Skripkin, Pirogov Russian National Research Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-0429-3117

1 Ostrovityanova St., Moscow 117997

Russian Federation

N.  M. Babadaev

Department of Faculty Therapy named after Academician A. I. Nesterov, Pirogov Russian National Research Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-0652-2884

1 Ostrovityanova St., Moscow 117997

Russian Federation

D. V. Somov

Department of Faculty Therapy named after Academician A. I. Nesterov, Pirogov Russian National Research Medical University, Ministry of Health of Russia

ORCID iD: 0000-0002-8874-3663

1 Ostrovityanova St., Moscow 117997

Russian Federation

References

  1. Hackett S., Coates L. Psoriatic arthritis: an up to date overview. Indian J Rheumatol 2020;15(1):45–51. doi: 10.4103/0973-3698.284751
  2. Lila A.M., Nasonov E.L., Korotaeva T.V. Psoriatic arthritis: pathogenetic features and innovative therapies. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice 2018;56(6):685–91. (In Russ.) doi: 10.14412/1995-4484-2018-685-691
  3. Ogdie A., Coates L.C., Gladman D.D. Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford) 2020;59(1):37–46. doi: 10.1093/rheumatology/kez383
  4. Korotaeva T.V., Korsakova Yu.I. Psoriatic arthritis: classification, clinical presentation, diagnosis, treatment. Naychno-prakticheskaya revmatologiya = Rheumatology Science and Practice 2018;56(1):60–9. (In Russ.) doi: 10.14412/1995-4484-2018-60-69
  5. Mishina O.S., Dvornikov A.S., Dontsova E.V. Analysis of the incidence of psoriasis and psoriatic arthritis in the Russian Federation for 2009-2011. Doktor Ru = Dr.Ru 2013;4(82):52–5.
  6. Toussi A., Maverakis N., Le S.T. et al. Updated therapies for the management of psoriatic arthritis. Clin Immunol 2020;220:108536. doi: 10.1016/j.clim.2020.108536
  7. Clegg D.O., Reda D.J., Mejias E. et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39(12):2013–20. doi: 10.1002/art.1780391210
  8. Mease P.J., Goffe B.S., Metz J. et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356(9227):385–90. doi: 10.1016/S0140-6736(00)02530-7
  9. Antoni C.E., Kavanaugh A., Kirkham B. et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis-controlled trial (IMPACT). Arthritis Rheum 2005;52(4):1227–36. doi: 10.1002/art.20967
  10. Mease P., Kivitz A., Burch F. et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50(7):2264–72. doi: 10.1002/art.20335
  11. Antoni C., Krueger G.G., de Vlam K. et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64(8):1150–57. doi: 10.1136/ard.2004.032268
  12. Mease P., Gladman D., Ritchlin C. Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: Results of ADEPT. Arthritis Rheum 2005;52(10):3279–89. doi: 10.1002/art.21306
  13. Kavanaugh A., Mcinnes I., Mease P. et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twentyfour-week efficacy and safety results of a randomized, placebocontrolled study. Arthritis Rheum 2009;60(4):976–86. doi: 10.1002/art.24403
  14. Mease P.J., Fleischmann R., Deodhar A.A. et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 doubleblind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014;73(1):48–55. doi: 10.1136/annrheumdis-2013-eular.2023
  15. Mease P.J. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness TherapyFatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken) 2011;63 (11):64–85. doi: 10.1002/acr.20577
  16. Mease P. Psoriatic arthritis and spondyloarthritis assessment and management update. Curr Opin Rheumatol 2013;25(3):287–96. doi: 10.1136/ard.2010.140582
  17. Mease P., Collier D., Karki C. et al. Persistence and predictors of biologic TNFi therapy among biologic naïve psoriatic arthritis patients in a US registry. Arthritis Rheum 2014;66(10):abs 1853. doi: 10.21203/rs.3.rs-78064/v1
  18. Fagerli K.M., Lie E., van der Heijde D. et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014;73(1):132–7. doi: 10.1136/annrheumdis-2012-202347
  19. Jorgensen T.S., Kristensen L.E., Christensen R. et al. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologic’s registry. Rheumatology (Oxford) 2015;54(12):2156–65. doi: 10.1093/rheumatology/kev216
  20. Mease P.J., Gladman D.D., Keystone E.C. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double-blind, placebocontrolled study. Arthritis Rheum 2006;54(5):1638–45. doi: 10.1002/art.21870
  21. Mease P.J. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis 2011;70(1):77–84. doi: 10.1136/ard.2010.140582
  22. Patel D.D., Lee D.M., Kolbinger F. et al. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013;72(2):116–23. doi: 10.14412/1996-7012-2013-04
  23. Van den Berg W.B., Mclnnes I.B. Th17 cells and IL-17a – focus on immunopathogenesis and therapeutics. Semin Arthritis Rheum 2013;43(2):158–70. doi: 10.1016/j.semarthrit.2013.04.006
  24. Frleta M., Siebert S., Mclnnes I.B. The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment. Curr Rheumatol Rep 2014;16(4):414. doi: 10.1007/s11926-014-0414-y
  25. Lories R.J., Mclnnes I.B. Primed for inflammation: enthesisresident T cells. Nat Med 2012;18(7):1018–9. doi: 10.1038/nm.2854
  26. McGonagle D., Lories R.J., Tan A.L. et al. The concept of a “synovio-entheseal complex” and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007;56(8):2482–91. doi: 10.1002/art.22758
  27. Mease P.J. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 2015;27(2):127–33. doi: 10.1097/BOR.0000000000000147
  28. Novartis. COSENTYX® (secukinumab) injection: US prescribing information. 2020. https://dailymed.nlm.nih.gov. Accessed 18 Jan 2021.
  29. European Medicines Agency. Secukinumab (Cosentyx): EU summary of product characteristics. 2020. https://www.ema.europa.eu. Accessed 18 Jan 2021.
  30. Mease P.J., Mclnnes I.B., Kirkham B. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 2015;373(14):1329–39. doi: 10.1056/NEJMoa1412679
  31. Mclnnes I.B., Mease P.J., Kirkham B. Secukinumab, a human antiinterleukin-17A monoclonal antibody, in patients with psoriatic Secukinumab: A Review 493 arthritis (FUTURE 2): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet 2015;386(9999):1137–46. doi: 10.1016/S0140-6736(15)61134-5
  32. Nash P., Mease P.J., McInnes I.B. et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther 2018;20(1):47. doi: 10.1186/s13075-018-1551-x
  33. Kivitz A.J., Nash P., Tahir H. et al. Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study. Rheumatol Ther 2019;6(3):393–407. doi: 10.1007/s40744-019-0163-5
  34. Mease P., van der Heijde D., Landewe R. et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis 2018;77(6):890–7. doi: 10.1136/annrheumdis-2017-212687
  35. Baraliakos X., Gossec L., Pournara E. et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis 2021;80(5):582–90. doi: 10.1136/annrheumdis2020-218808
  36. Оstino M., Schett G., Lopez-Rdz A. et al. Secukinumab signifcantly decreased joint synovitis measured by power doppler ultrasonography in biologic-naive patients with active psoriatic arthritis: primary (12-week) results from a randomized, placebo-controlled phase III study. Br J Rheumatol 2020; 60(1):100–1. doi: 10.1093/rheumatology/keab247.182
  37. Mclnnes I.B., Behrens F., Mease P.J. et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active controlled, phase 3b trial. Lancet 2020;395(10235):1496–5. doi: 10.1016/S0140-6736(20)31205-8
  38. Van der Heijde D., Mease P.J., Landewe R.B.M. et al. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology (Oxford) 2020;59(6):1325–34. doi: 10.1093/rheumatology/kez420
  39. Mease P.J., Landewe R.B.M., Rahman P. et al. Subcutaneous secukinumab 300 mg and 150 mg provides sustained inhibition of radiographic progression in psoriatic arthritis over 2 years: results from the phase 3 FUTURE-5 trial [abstract no. LB0006]. Ann Rheum Dis 2019;78(2):262. doi: 10.1136/annrheumdis-2019-eular.8808
  40. Mclnnes I.B., Mease P.J., Ritchlin C.T. et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2-year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford) 2017;56(11):1993–2003. doi: 10.1093/rheumatology/kex301
  41. Kavanaugh A., Mease P.J., Reimold A.M. et al. Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study. Arthritis Care Res 2017;69(3):347–55. doi: 10.1002/acr.23111.
  42. Mease P.J., Kavanaugh A., Reimold A. et al. Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study. ACR Open Rheumatol 2020;2(1):18–25. doi: 10.1002/acr2.11097
  43. Mease P.J., Kavanaugh A., Reimold A. et al. Secukinumab in the treatment of psoriatic arthritis: efcacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open 2018;4(2):e000723. doi: 10.1136/rmdopen-2018-000723
  44. Nash P., McInnes I.B., Rahman P. et al. Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year results from the phase 3 FUTURE 2 study [abstract no. THU0322]. Ann Rheum Dis 2018;77(2):379. doi: 10.1136/rmdopen-2018-000723.
  45. Mclnnes I.B., Mease P.J., Kivitz A.J. et al. Long-term efcacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. Lancet Rheumatol 2020;2(4):e227–35. doi: 10.1016/S2665-9913(20)30036-9
  46. Van der Heijde D., Landewe R.B., Mease P.J. et al. Secukinumab provides signifcant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. Arthritis Rheumatol 2016;68(8):1914–21. doi: 10.1002/art.39685
  47. Strand V., Mease P., Gossec L. et al. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Ann Rheum Dis 2017;76(1):203–7. doi: 10.1136/annrheumdis-2015-209055
  48. Mclnnes I.B., Mease P.J., Schett G. et al. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. Arthritis Res Ther 2018;20(1):113. doi: 10.1136/annrheumdis-2015-209055
  49. Coates L.C., Mease P.J., Gossec L. et al. Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study. Arthritis Care Res 2018;70(10):1529–35. doi: 10.1002/acr.23537
  50. Coates L.C., Gladman D.D., Nash P. et al. Secukinumab provides sustained PASDAS-defned remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. Arthritis Res Ther 2018;20(1):272. doi: 10.1186/s13075-018-1773-y
  51. Coates L.C., Nash P., Kvien T.K. et al. Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. Semin Arthritis Rheum 2020;50(4):709–18. doi: 10.1016/j.semarthrit.2020.03.015
  52. D’Agostino M., Schett G., Lopez-Rdodriguez A. et al. Secukinumab significantly decreased joint synovitis measured by power doppler ultrasonography in biologic-naive patients with active psoriatic arthritis: primary (12-week) results from a randomized, placebo-controlled phase 3 study. Rheumatology (Oxford) 2021;60(1):P187. doi: 10.1093/rheumatology/keab247.182
  53. Chimenti M.S., Fonti G.L., Conigliaro P. et al. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Expert Opin Biol Ther 2020;20(7):813–21. doi: 10.1080/14712598.2020.1761957
  54. Conaghan P.G., Holdsworth E., Tian H. et al. Real world efectiveness of secukinumab in psoriatic arthritis: fndings from a recent cross-sectional survey of rheumatologists and patients in Europe [abstract no. AB0755]. Ann Rheum Dis 2020;79(1):1674–5. doi: 10.1136/annrheumdis2020-eular.1374
  55. Kiltz U., Peterlik D., Winkelmann V. et al. AQUILA study in Germany – real world data on secukinumab’s efectiveness in psoriatic arthritis patients – results from an interim analysis [abstract no. FRI0405]. Ann Rheum Dis 2019;78(2):889–90. doi: 10.1136/annrheumdis-2019-eular.436
  56. Mease P.J., Blachley T., Glynn M. et al. Secukinumab improves clinical and patient-reported outcomes at 6 months among patients with psoriatic arthritis in the US-based Corrona psoriatic arthritis/ spondyloarthritis (PsA/SpA) registry [abstract no. SAT0429]. Ann Rheum Dis 2020;79(1):1169. doi: 10.1136/annrheumdis-2020-eular.1014
  57. Favalli E.G., Marchesoni A., Balduzzi S. et al. Effectiveness and retention rate of secukinumab for psoriatic arthritis and axial spondyloarthritis: real-life data from the Italian LORHEN registry [abstract no. FRI0273]. Ann Rheum Dis 2020;79(1):722–3. doi: 10.1136/annrheumdis-2020-eular.3197
  58. Lorenzin M., Carletto A., Foti R. et al. Effectiveness and safety of secukinumab in naive or TNF-inhibitors failure psoriatic arthritis patients in real life: a 24-months prospective multicenter study [abstract no. FRI0284]. Ann Rheum Dis 2020;79(1):730. doi: 10.1136/annrheumdis-2020-eular.3702
  59. Magrey M., Bozyczko M., Wolin D. et al. Evaluation of the feasibility of a web-based survey to assess patient-reported symptom improvement and treatment satisfaction among patients with psoriatic arthritis receiving secukinumab. Clin Drug Investig 2019;39(12):1205–12. doi: 10.1007/s40261-019-00856-8
  60. Martin L.M., Valero M., Emperiale V. et al. Real-world experience of secukinumab for psoriatic arthritis [abstract no. FRI0448]. Ann Rheum Dis. 2019;78(2):915. doi: 10.1136/annrheumdis-2019-eular.7452
  61. Holdsworth E., Booth N., Lobosco S. et al. Real-world physician satisfaction with secukinumab in psoriatic arthritis and ankylosing spondylitis in Europe [abstract no. THU0635]. Ann Rheum Dis 2019;78(2):611–2. doi: 10.1136/annrheumdis-2019-eular.4167
  62. Michelsen B., Georgiadis S., Giuseppe D.I. et al. Secukinumab effectiveness in 1543 patients with psoriatic arthritis treated in routine clinical practice in 13 European countries in the EuroSpA research collaboration network [abstract no. SAT0430]. Ann Rheum Dis 2020;79(1):1169–71. doi: 10.1136/annrheumdis2020-eular.1413
  63. Kiltz U., Peterlik D., Winkelmann V. AQUILA study in Germany – real world adherence and persistence of secukinumab treatment in ankylosing spondylitis and psoriatic arthritis patients – an interim analysis [abstract no. AB0705]. Ann Rheum Dis. 2019;78(2):1814–5. doi: 10.1136/annrheumdis-2019-eular.435
  64. Oelke K.R., Chambenoit O., Majjhoo A.Q. et al. Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database. J Comp Ef Res 2019;8(8):607–22. doi: 10.2217/cer-2019-002
  65. Elewski B.E., Baddley J.W., Deodhar A.A. et al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. JAMA Dermatol 2021;157(1):43–51. doi: 10.1001/jamadermatol.2020.3257
  66. Deodhar A., McInnes I., Baraliakos X. et al. Secukinumab demonstrates a consistent safety profle in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: updated pooled safety analysis [abstract no. FRI0272]. Ann Rheum Dis 2020;79(1):722. doi: 10.1093/rheumatology/kez107.073
  67. Deodhar A., Gladman D.D., Mclnnes I.B. et al. Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis. J Rheumatol 2020;47(4):539–47. doi: 10.3899/jrheum.190116
  68. Gossec L., Baraliakos X., Kerschbaumer A. et al. EULAR recommendations for the management of psoriatic rthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79(6):700–12. doi: 10.1136/annrheumdis-2020-217159
  69. Coates L.C., Kavanaugh A., Mease P.J. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 2016;68(5):1060–71. doi: 10.1002/art.39573
  70. Singh J.A., Guyatt G., Ogdie A. et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol 2019;71(1):5–32. doi: 10.1002/acr.23789

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Shostak N.A., Andriyashkina D.Y., Dvornikov A.S., Babadaev N.M., Somov D.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36931 от  21.07.2009.